CL2017002314A1 - Métodos de preparación de polinucleótidos usando composiciones salinas de cationes multivalentes - Google Patents

Métodos de preparación de polinucleótidos usando composiciones salinas de cationes multivalentes

Info

Publication number
CL2017002314A1
CL2017002314A1 CL2017002314A CL2017002314A CL2017002314A1 CL 2017002314 A1 CL2017002314 A1 CL 2017002314A1 CL 2017002314 A CL2017002314 A CL 2017002314A CL 2017002314 A CL2017002314 A CL 2017002314A CL 2017002314 A1 CL2017002314 A1 CL 2017002314A1
Authority
CL
Chile
Prior art keywords
polynucleotide
salt
composition
methods
multivalent cations
Prior art date
Application number
CL2017002314A
Other languages
English (en)
Inventor
Premchandran H Ramiya
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of CL2017002314A1 publication Critical patent/CL2017002314A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>Los aspectos de la descripción incluyen métodos para la preparación de un polinucleótido. En algunas modalidades, el método incluye poner en contacto una primera composición de polinucleótidos que incluye: un polinucleótido que tiene una secuencia de 7 o más subunidades nucleósido donde al menos dos de las subunidades nucleósido están unidas por un enlace entre subunidades de tiofosforamidato N3'→P5'; y reactivos y productos sintéticos no objetivo; con una sal de cationes multivalente para precipitar una primera sal de polinucleótidos que incluye al menos un contraión de cationes multivalente; y separar la sal de polinucleótidos de la primera composición de polinucleótidos en contacto para producir una segunda composición de polinucleótidos que incluye la primera sal de polinucleótidos. En determinadas modalidades, el método incluye además poner en contacto la primera sal de polinucleótidos con un soporte de cromatografía de fase inversa; y eluir a partir del soporte de cromatografía una tercera composición de polinucleótidos que incluye una segunda sal de polinucleótidos. También se proporcionan composiciones que incluyen una sal del polinucleótido que incluye al menos un contraión de cationes multivalentes.</p>
CL2017002314A 2015-04-23 2017-09-13 Métodos de preparación de polinucleótidos usando composiciones salinas de cationes multivalentes CL2017002314A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562151891P 2015-04-23 2015-04-23

Publications (1)

Publication Number Publication Date
CL2017002314A1 true CL2017002314A1 (es) 2018-05-04

Family

ID=55911083

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002314A CL2017002314A1 (es) 2015-04-23 2017-09-13 Métodos de preparación de polinucleótidos usando composiciones salinas de cationes multivalentes

Country Status (36)

Country Link
US (2) US10745687B2 (es)
EP (1) EP3286203B1 (es)
JP (4) JP2018513127A (es)
KR (1) KR102401252B1 (es)
CN (2) CN113564168B (es)
AU (2) AU2016250576C1 (es)
BR (1) BR112017019627B1 (es)
CA (1) CA2978191C (es)
CL (1) CL2017002314A1 (es)
CO (1) CO2017009217A2 (es)
CY (1) CY1123197T1 (es)
DK (1) DK3286203T3 (es)
EA (1) EA035885B1 (es)
ES (1) ES2798270T3 (es)
HR (1) HRP20201218T1 (es)
HU (1) HUE051148T2 (es)
IL (1) IL254222A0 (es)
LT (1) LT3286203T (es)
MA (2) MA42569B1 (es)
MD (1) MD3286203T2 (es)
ME (1) ME03811B (es)
MX (1) MX383293B (es)
MY (1) MY187804A (es)
PE (2) PE20221275A1 (es)
PH (1) PH12017501927B1 (es)
PT (1) PT3286203T (es)
RS (1) RS60645B1 (es)
SA (1) SA517390103B1 (es)
SG (2) SG10201909816PA (es)
SI (1) SI3286203T1 (es)
SM (1) SMT202000389T1 (es)
TN (1) TN2017000411A1 (es)
TW (1) TWI736532B (es)
UA (1) UA124521C2 (es)
WO (1) WO2016172346A1 (es)
ZA (1) ZA201706041B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113564168B (zh) 2015-04-23 2024-10-25 美国杰龙生物医药公司 使用多价阳离子盐组合物制备多核苷酸的方法
CN108430456B (zh) 2015-10-22 2022-01-18 摩登纳特斯有限公司 癌症疫苗
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
CN110121364A (zh) 2016-12-19 2019-08-13 文塔纳医疗系统公司 肽核酸缀合物
WO2019036683A1 (en) * 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
CN111542606A (zh) * 2017-09-22 2020-08-14 科罗拉多州立大学董事会法人团体 硫吗啉代寡核苷酸用于治疗肌肉营养不良
WO2019120635A1 (en) 2017-12-18 2019-06-27 Ventana Medical Systems, Inc. Peptide nucleic acid conjugates

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
DE69133235T2 (de) 1990-08-31 2003-11-20 The Regents Of The University Of Minnesota, Minneapolis Verfahren zur Herstellung von Harzen für die Feststoff-Peptidsynthese
US5281701A (en) 1991-07-12 1994-01-25 Applied Biosystems, Inc. Process and compounds for RNA synthesis
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
EP0754242A4 (en) 1994-03-18 1997-06-11 Lynx Therapeutics Inc SYNTHESIS AND SUBSTANCE, HYBRIDIZATION AND NUCLEASE-RESISTANT PROPERTIES OF OLIGONUCLEOTID-N3'-m (7) P5'-PHOSPHORAMIDATE
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
US6114519A (en) 1997-10-15 2000-09-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized oligonucleotides
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
AU767646B2 (en) 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
JP2002060341A (ja) 2000-08-21 2002-02-26 Terumo Corp 止血剤
EP1379689B1 (en) 2001-03-23 2012-09-26 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
SI3342425T1 (sl) * 2003-09-09 2020-04-30 Geron Corporation Modificirani oligonukleotidi za inhibicijo telomeraze
TW200540180A (en) 2004-05-28 2005-12-16 Sankyo Co Telomerase inhibitor ena oligonucleotide
CN100558739C (zh) 2004-07-02 2009-11-11 杰龙公司 合成被保护的3’-氨基核苷单体
WO2007041201A2 (en) * 2005-10-03 2007-04-12 Applera Corporation Compositions, methods, and kits for amplifying nucleic acids
US9109015B2 (en) 2006-11-01 2015-08-18 Biogen Ma Inc Method of isolating biomacromolecules using low pH and divalent cations
KR20150039873A (ko) * 2010-08-20 2015-04-13 레플리코르 인코포레이티드 올리고뉴클레오타이드 킬레이트 복합체
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
AR091065A1 (es) 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
KR20210072137A (ko) * 2012-06-14 2021-06-16 라이프 테크놀로지스 코포레이션 폴리머라제 연쇄 반응 (pcr)을 위한 신규 조성물, 방법 및 키트
IL280144B2 (en) * 2012-12-07 2025-05-01 Geron Corp Use of telomerase inhibitors to treat bone marrow culture disorders and bone marrow culture tumors
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
CN113564168B (zh) 2015-04-23 2024-10-25 美国杰龙生物医药公司 使用多价阳离子盐组合物制备多核苷酸的方法

Also Published As

Publication number Publication date
CO2017009217A2 (es) 2018-02-20
UA124521C2 (uk) 2021-10-05
JP2018513127A (ja) 2018-05-24
BR112017019627B1 (pt) 2022-11-29
TW201706284A (zh) 2017-02-16
SI3286203T1 (sl) 2020-10-30
MA42157A (fr) 2018-02-28
CN107429247A (zh) 2017-12-01
JP2021152079A (ja) 2021-09-30
TN2017000411A1 (en) 2019-01-16
NZ735042A (en) 2021-11-26
SA517390103B1 (ar) 2021-07-14
WO2016172346A1 (en) 2016-10-27
ME03811B (me) 2021-04-20
BR112017019627A2 (pt) 2018-05-15
AU2016250576C1 (en) 2021-05-06
CA2978191A1 (en) 2016-10-27
CN113564168A (zh) 2021-10-29
AU2016250576B2 (en) 2021-02-04
MX383293B (es) 2025-03-13
HRP20201218T1 (hr) 2020-12-11
CN113564168B (zh) 2024-10-25
AU2021202803A1 (en) 2021-06-03
US10745687B2 (en) 2020-08-18
IL254222A0 (en) 2017-10-31
CA2978191C (en) 2022-10-04
PH12017501927A1 (en) 2018-03-05
EP3286203B1 (en) 2020-05-06
MX2017011642A (es) 2017-11-02
LT3286203T (lt) 2020-07-27
PE20171785A1 (es) 2017-12-27
EA035885B1 (ru) 2020-08-27
HUE051148T2 (hu) 2021-03-01
JP2022168017A (ja) 2022-11-04
ES2798270T3 (es) 2020-12-10
PH12017501927B1 (en) 2022-09-02
TWI736532B (zh) 2021-08-21
AU2016250576A1 (en) 2017-09-21
PE20221275A1 (es) 2022-09-01
MD3286203T2 (ro) 2020-08-31
SG10201909816PA (en) 2019-11-28
SMT202000389T1 (it) 2020-09-10
MA42569B1 (fr) 2020-08-31
CY1123197T1 (el) 2021-10-29
SG11201707893RA (en) 2017-11-29
KR102401252B1 (ko) 2022-05-24
PT3286203T (pt) 2020-07-08
US20200339975A1 (en) 2020-10-29
JP2025061848A (ja) 2025-04-11
HK1251234A1 (en) 2019-01-25
DK3286203T3 (da) 2020-06-02
KR20170138399A (ko) 2017-12-15
US11441144B2 (en) 2022-09-13
EP3286203A1 (en) 2018-02-28
CN107429247B (zh) 2021-08-13
EA201791753A1 (ru) 2018-04-30
ZA201706041B (en) 2020-11-25
US20160312227A1 (en) 2016-10-27
MY187804A (en) 2021-10-26
RS60645B1 (sr) 2020-09-30

Similar Documents

Publication Publication Date Title
CO2017009217A2 (es) Métodos de preparación de polinucleótidos de tiofosforamidato n3’→p5’ usando composiciones salinas de cationes multivalentes
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
CL2016002010A1 (es) Métodos y sistemas para generar mapas colaborativos compartidos
MX386500B (es) Anticuerpos contra icos
MX2017011329A (es) Productos terapeuticos de anticuerpos que se enlazan a cd47.
CO2018002196A2 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
MX2018005551A (es) Anticuerpos que se unen especificamente a pd-1, y sus usos.
BR112014009066B8 (pt) molécula de ácido nucleico, método para a sintetização de uma molécula de dna de triciclo-fosforotioato e composição farmacêutica
CL2018001770A1 (es) Composiciones de decil mercaptanos mezclados y uso de las mismas como colectoras de productos químicos de minería
BR112015021240A2 (pt) processo para sal de sódio de (2s, 5r)-2-carboxamido-7-oxo-6-sulfo-oxi-1,6-diaza-biciclo[3.2.1]octano
MX2019007248A (es) Enzimas de polimerizacion para reacciones de secuenciacion.
BR112017007411A2 (pt) método em a máquina de plantio de mudas e máquina de plantio de mudas
BR112017000135B8 (pt) Processo para a preparação de ácidos 4-alcóxi-3-hidroxipicolínico
MX2017008410A (es) Reduccion selectiva de residuos cisteina en anticuerpos il-17.
BR112017015414A2 (pt) máquina fresadora e método de aplicação da máquina fresadora
MX385237B (es) Aleaciones magneticas de cobre.
BR112016025196A2 (pt) composições de oligonucleotídeo e métodos de fazê-las
BR112014015288A2 (pt) máquina e processo para tornear pelo menos ressaltos planos de um eixo de manivela que circunda pinos de manivela
BR112019001409A2 (pt) células renais bioativas para o tratamento de doença renal crônica
CR20130662A (es) Anticuerpos a adp-ribosil ciclasa 2
MX375894B (es) Uso de acido alcanosulfonico para limpieza en las industrias azucareras.
DOP2015000294A (es) Preparado farmacéutico
BR112017026203A2 (pt) método de geração de uma estratégia de produção para a explotação de um reservatório de hidrocarbonetos em um ambiente natural
BR112018074079A2 (pt) unidade de produção de sumo que tem um apoio
CY1122334T1 (el) Νεες κρυσταλλικες mopφeς του αλατος μονονατριου της φορμασουλφουρονης